Excerpt: NRx has a cluster of shots on goal — KETAFREE/NRX-100, NRX-101 paired with TMS, and the HOPE Therapeutics clinic roll-up — all converging on a 2026 FDA catalyst window that makes timing and cash the two things that matter most. The hub lays out each program, the catalyst calendar and the funding/dilution risks.
Full write-up (free, no signup): https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/
Not financial advice — just research.